Triptorelin Market Analysis

  • Report ID: 5019
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Triptorelin Market Analysis

Triptorelin Segmentation

Drug Type (Triptorelin Pamoate, Triptorelin Acetate, Triptorelin Embonate)

Triptorelin market from the triptorelin embonate segment is expected to generate the highest revenue by the end of 2036. The growth of the segment can be attributed to the growing prevalence of prostate cancer since it is highly used in treating it. However, this is also used in treating endometriosis, and uterine fibroids. This is because, triptorelin embonate functions by restricting the release of hormones known as gonadotropins, which stimulate the testicles or ovaries.

Distribution Channel (Online Pharmacy, Hospital Pharmacy, others)

The hospital pharmacy segment in the triptorelin market is poised to have noteworthy growth over the forecast period. This segment expansion is expected to be influenced by rising hospital admission for gynecological disorders, or cancer. Also, these drugs are usually prescribed by a medical professional in the hospital, hence the attached pharmacies to the hospital make it convenient for the patient to find their prescribed drugs.

Our in-depth analysis of the global market includes the following segments:

 

         Drug Type

  • Triptorelin Pamoate
  • Triptorelin Acetate
  • Triptorelin Embonate

         Application

  • Prostate Cancer
  • Radical Prostatectomy
  • Endometriosis
  • Salivary Gland Cancer
  • Central Precocious Puberty

        Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5019
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of triptorelin is estimated at USD 11.06 Billion.

The triptorelin market size was valued at USD 10.53 Billion in 2023 and is likely to reach USD 20.61 Billion by 2036, registering around 5.3% CAGR during the forecast period i.e., between 2024-2036. The major factors driving the growth of the market are the growing prevalence of HIV, the rise in prostate cancer among people, and the surge in the number of women suffering from endometriosis.

North America industry is set to have the highest gain by 2036, backed by growing demand for hormone therapy among men.

Ipsen Pharma, Bachem, Chengdu Tiantaishan pharmaceutical, Ferring Pharmaceuticals, Tecnofarma SA, Dr. Reddy's Laboratories Ltd, Arbor Pharmaceutical, Inc., Teva Pharmaceutical Industries Ltd., Debiopharm International SA, Verity Pharmaceuticals Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample